Mariner
BCAX

Mariner’s Bicara Therapeutics BCAX Stock Holding History

Mariner’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.09M Sell
55,037
-9,525
-15% -$164K ﹤0.01% 1904
2025
Q4 		$1.09M Buy
64,562
+1,902
+3% +$32.5K ﹤0.01% 1894
2025
Q3 		$989K Buy
62,660
+50,223
+404% +$562K ﹤0.01% 1914
2025
Q2 		$116K Buy
+12,437
New +$148K ﹤0.01% 3212

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Mariner's BCAX Position: Q1 2026 in Review

Mariner reduced its Bicara Therapeutics (BCAX) stake by 15% in Q1 2026, selling an estimated $164K and leaving 55,037 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #1904.

Mariner first reported a position in BCAX in Q2 2025 and has held it in 4 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Mariner held 55,037 shares of Bicara Therapeutics worth $1.09M as of Q1 2026.
  • Mariner sold 9,525 Bicara Therapeutics shares in Q1 2026, an estimated $164K.
  • Bicara Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #1904 holding.
  • Mariner first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.